1235581-91-5Relevant articles and documents
Effects of hydrogen sulfide-releasing L-DOPA derivatives on glial activation: Potential for treating Parkinson disease
Lee, Moonhee,Tazzari, Valerio,Giustarini, Daniela,Rossi, Ranieri,Sparatore, Anna,Del Soldato, Piero,McGeer, Edith,McGeer, Patrick L.
experimental part, p. 17318 - 17328 (2011/05/06)
The main lesion in Parkinson disease (PD) is loss of substantia nigra dopaminergic neurons. Levodopa (L-DOPA) is the most widely used therapy, but it does not arrest disease progression. Some possible contributing factors to the continuing neuronal loss a